References
- Vajaria BN, Patel PS. Glycosylation: a hallmark of cancer? Glycoconj J. 2017 Apr;34(2):147–156.
- Silsirivanit A. Glycosylation markers in cancer. Adv Clin Chem. 2019;89:189–213.
- Saentaweesuk W, Silsirivanit A, Vaeteewoottacharn K, et al. Clinical significance of GalNAcylated glycans in cholangiocarcinoma: values for diagnosis and prognosis. Clin Chim Acta. 2018;477:66–71.
- Matsuda A, Kuno A, Kawamoto T, et al. Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma. Hepatology. 2010 Jul;52(1):174–182.
- Detarya M, Sawanyawisuth K, Aphivatanasiri C, et al. The O-GalNAcylating enzyme GALNT5 mediates carcinogenesis and progression of cholangiocarcinoma via activation of AKT/ERK signaling. Glycobiology. 2020 Apr 20;30(5):312–324.
- Phoomak C, Silsirivanit A, Park D, et al. O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1. Oncogene. 2018 Oct;37(42):5648–5665.
- Silsirivanit A, Araki N, Wongkham C, et al. CA-S27: a novel Lewis a associated carbohydrate epitope is diagnostic and prognostic for cholangiocarcinoma. Cancer Sci. 2013 Oct;104(10):1278–1284.
- Juntavee A, Sripa B, Pugkhem A, et al. Expression of sialyl Lewis(a) relates to poor prognosis in cholangiocarcinoma. World J Gastroenterol. 2005 Jan 14;11(2):249–254.
- Indramanee S, Sawanyawisuth K, Silsirivanit A, et al. Terminal fucose mediates progression of human cholangiocarcinoma through EGF/EGFR activation and the Akt/Erk signaling pathway. Sci Rep. 2019 Nov 21;9(1):17266.
- Wattanavises S, Silsirivanit A, Sawanyawisuth K, et al. Increase of MAL-II binding alpha2,3-sialylated glycan is associated with 5-FU resistance and short survival of cholangiocarcinoma patients. Medicina (Kaunas). 2019 Nov 28;55(12):1–10.
- Bamrungphon W, Prempracha N, Bunchu N, et al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett. 2007 Mar 18;247(2):301–308.
- Silsirivanit A, Matsuda A, Kuno A, et al. Multi-serum glycobiomarkers improves the diagnosis and prognostic prediction of cholangiocarcinoma. Clin Chim Acta. 2020 Jul 11;510:142–149.
- Costa AF, Campos D, Reis CA, et al. Targeting glycosylation: a new road for cancer drug discovery. Trends Cancer. 2020 Sep 6;6(9):757–766.
- Esko JD, Bertozzi C, Schnaar RL, et al. Chemical Tools for Inhibiting Glycosylation. In: Varki A, Cummings RD, Esko JD, et al., editors Essentials of Glycobiology. (NY): Cold Spring Harbor; 2015. p. 701–712. rd.
- Mereiter S, Balmana M, Campos D, et al. Glycosylation in the era of cancer-targeted therapy: where are we heading? Cancer Cell. 2019 Jul 8;36(1):6–16.
- Yau T, Dan X, Ng CC, et al. Lectins with potential for anti-cancer therapy. Molecules. 2015 Feb 26;20(3):3791–3810.